These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 10861700)
1. Enhanced cell death in NR-S1 tumor by photodynamic therapy: possible involvement of Fas and Fas ligand system. Yokota T; Ikeda H; Inokuchi T; Sano K; Koji T Lasers Surg Med; 2000; 26(5):449-60. PubMed ID: 10861700 [TBL] [Abstract][Full Text] [Related]
2. Advantages of laserphyrin compared with photofrin in photodynamic therapy for bile duct carcinoma. Nonaka T; Nanashima A; Nonaka M; Uehara M; Isomoto H; Nonaka Y; Nagayasu T J Hepatobiliary Pancreat Sci; 2011 Jul; 18(4):592-600. PubMed ID: 21360081 [TBL] [Abstract][Full Text] [Related]
3. Photodynamic therapy with hypericin induces vascular damage and apoptosis in the RIF-1 mouse tumor model. Chen B; Roskams T; Xu Y; Agostinis P; de Witte PA Int J Cancer; 2002 Mar; 98(2):284-90. PubMed ID: 11857421 [TBL] [Abstract][Full Text] [Related]
4. Fas-mediated apoptosis of melanoma cells and infiltrating lymphocytes in human malignant melanomas. Shukuwa T; Katayama I; Koji T Mod Pathol; 2002 Apr; 15(4):387-96. PubMed ID: 11950912 [TBL] [Abstract][Full Text] [Related]
5. [The evaluation of Fas/Fas ligand system in renal cell carcinoma--the effect of preoperative interferon-alpha therapy]. Sejima T; Miyagawa I Nihon Hinyokika Gakkai Zasshi; 1999 Oct; 90(10):826-32. PubMed ID: 10565161 [TBL] [Abstract][Full Text] [Related]
6. Expression of fas/fas ligand (fasL) and its involvement in infiltrating lymphocytes in hepatocellular carcinoma (HCC). Fukuzawa Y; Takahashi K; Furuta K; Tagaya T; Ishikawa T; Wada K; Omoto Y; Koji T; Kakumu S J Gastroenterol; 2001 Oct; 36(10):681-8. PubMed ID: 11686478 [TBL] [Abstract][Full Text] [Related]
7. Fas ligand upregulation is an early event in colonic carcinogenesis. Bennett MW; O'Connell J; Houston A; Kelly J; O'Sullivan GC; Collins JK; Shanahan F J Clin Pathol; 2001 Aug; 54(8):598-604. PubMed ID: 11477113 [TBL] [Abstract][Full Text] [Related]
8. Effects of FasL expression in oral squamous cell cancer. Fang L; Sun L; Hu FF; Chen QE Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738 [TBL] [Abstract][Full Text] [Related]
9. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer. Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372 [TBL] [Abstract][Full Text] [Related]
10. Role of fas ligand in uveal melanoma-induced liver damage. Repp AC; Mayhew ES; Howard K; Alizadeh H; Niederkorn JY Graefes Arch Clin Exp Ophthalmol; 2001 Oct; 239(10):752-8. PubMed ID: 11760036 [TBL] [Abstract][Full Text] [Related]
11. Enhanced susceptibility of mouse squamous cell carcinoma to photodynamic therapy combined with low-dose administration of cisplatin. Uehara M; Inokuchi T; Ikeda H J Oral Maxillofac Surg; 2006 Mar; 64(3):390-6. PubMed ID: 16487799 [TBL] [Abstract][Full Text] [Related]
12. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174 [TBL] [Abstract][Full Text] [Related]
13. Localization of Fas and Fas ligand in bone marrow cells demonstrating myelodysplasia. Kitagawa M; Yamaguchi S; Takahashi M; Tanizawa T; Hirokawa K; Kamiyama R Leukemia; 1998 Apr; 12(4):486-92. PubMed ID: 9557605 [TBL] [Abstract][Full Text] [Related]
14. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape? Ni X; Hazarika P; Zhang C; Talpur R; Duvic M Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580 [TBL] [Abstract][Full Text] [Related]
15. Action and mechanism of Fas and Fas ligand in immune escape of gallbladder carcinoma. Xu LN; Zou SQ; Wang JM World J Gastroenterol; 2005 Jun; 11(24):3719-23. PubMed ID: 15968727 [TBL] [Abstract][Full Text] [Related]
16. Correlation of Fas/FasL expression to cell apoptosis in Epstein-Barr virus-associated gastric carcinoma. He D; Xiao L; Chen JN; Liang Q; Shao CK Chin J Cancer; 2010 Mar; 29(3):283-7. PubMed ID: 20193111 [TBL] [Abstract][Full Text] [Related]
17. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis. Osaki M; Kase S; Kodani I; Watanabe M; Adachi H; Ito H Gastric Cancer; 2001; 4(4):198-205. PubMed ID: 11846063 [TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical characterization of Fas (CD95) and Fas Ligand (FasL/CD95L) expression in the injured brain: relationship with neuronal cell death and inflammatory mediators. Grosjean MB; Lenzlinger PM; Stahel PF; Yatsiv I; Shohami E; Trentz O; Kossmann T; Morganti-Kossmann MC Histol Histopathol; 2007 Mar; 22(3):235-50. PubMed ID: 17163398 [TBL] [Abstract][Full Text] [Related]
19. Involvement of Fas/Fas ligand in the induction of apoptosis in chronic sialadenitis of minor salivary glands including Sjögren's syndrome. Shibata Y; Hishikawa Y; Izumi S; Fujita S; Yamaguchi A; Koji T Hum Cell; 2002 Mar; 15(1):52-60. PubMed ID: 12126064 [TBL] [Abstract][Full Text] [Related]
20. Possible role of Fas/Fas ligand-mediated apoptosis in the pathogenesis of fixed drug eruption. Choi HJ; Ku JK; Kim MY; Kang H; Cho SH; Kim HO; Park YM Br J Dermatol; 2006 Mar; 154(3):419-25. PubMed ID: 16445769 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]